SanBio announced the results of the Phase 2 STEMTRA trial of SB623 as a treatment for chronic motor deficit from traumatic brain injury, at 2019 World Federation of Neurosurgical Societies Special World Congress
SanBio announced the results of the Phase 2 STEMTRA trial of SB623 as a treatment for chronic motor deficit from traumatic brain injury was presented at the Military Health System Research Symposium 2019
Bijan Nejadnik, M.D., appointed as Chief Medical Officer of SanBio
SB623, an Investigational Product, Granted Advanced Therapy Medicinal Product Classification by European Medicines Agency
AANS 2019: SB623 Demonstrated Statistically Significant Improvement in Motor Function Among Patients with Chronic Motor Deficit from Traumatic Brain Injury (TBI)
SanBio announces SB623 regenerative cell therapy for traumatic brain injury has received Ministry of Health, Labour and Welfare (MHLW) Sakigake designation
SanBio to give an encore presentation on the results of a Phase 2 STEMTRA trial regarding the use of regenerative cell medicine SB623 as a treatment for TBI at the 14th Korea–Japan Joint Conference on Surgery for Cerebral Stroke
SanBio to announce the results of a Phase 2 STEMTRA trial regarding the use of regenerative cell medicine SB623 as a treatment for TBI at an annual scientific meeting of the American Association of Neurological Surgeons
A Message to Patients from CEO Keita Mori regarding Topline Analytical Results of Clinical Trial Announced on January 29, 2019（94KB）
Q&A concerning the January 29, 2019 press release “SanBio Announces Topline Results from a Phase 2b Study in the U.S. Evaluating SB623, a Regenerative Cell Medicine for the Treatment of Patients with Chronic Stroke”（136KB）
